Table 4.1 ¨C Perinatal Hepatitis B Prevention Program: Outcomes by Jurisdiction

Key points

Data from CDC’s Perinatal Hepatitis B Prevention Program (PHBPP) from 64 jurisdictions reported 7,327 infants born to women with hepatitis B virus (HBV) infection during 2022, of whom 92% had received recommended prophylaxis at birth, 86% had completed three doses of vaccine by age 12 months, and 65% had received recommended post-vaccination serologic testing. Among infants with post-vaccination testing, seven were identified as cases of perinatal hepatitis B.
CDC 2023 Hepatitis B Surveillance Report perinatal hepatitis b prevention program

Outcomes of infants* born in 2022 to women with hepatitis B and managed by the CDC Perinatal Hepatitis B Prevention Program through December 31, 2023 — 64 US Jurisdictions

Outcomes of infants born in 2022 to persons with hepatitis B and managed by the CDC Perinatal Hepatitis B Prevention Program through the end of 2022 in 64 United States jurisdictions.
Hepatitis B vaccine administration Post-vaccination serologic testing
Grantee All infants managed* PEP Complete series by 12 months of age Complete series after 12 months of age Total with complete series Received† HBsAg positive Immune§
No. No. % No. % No. % No. % No. % No. % No. %
All jurisdications 7,327 6,707 92% 6,280 86% 128 2% 6,408 87% 4,729 65% 7 0% 4,380 93%
State
Alabama 36 35 97% 25 69% 0 0% 25 69% 25 69% 0 0% 24 96%
Alaska 21 13 62% 18 86% 0 0% 18 86% 1 5% 0 0% 0 0%
Arizona 122 113 93% 101 83% 4 3% 105 86% 70 57% 0 0% 63 90%
Arkansas 51 49 96% 42 82% 2 4% 44 86% 29 57% 0 0% 29 100%
California 1,013 941 93% 905 89% 14 1% 919 91% 594 59% 1 0% 546 92%
Colorado 85 82 96% 77 91% 2 2% 79 93% 68 80% 0 0% 64 94%
Connecticut 56 55 98% 56 100% 0 0% 56 100% 38 68% 0 0% 34 89%
Delaware 36 36 100% 18 50% 7 19% 25 69% 23 64% 0 0% 19 83%
Florida 319 285 89% 249 78% 5 2% 254 80% 120 38% 0 0% 109 91%
Georgia 215 210 98% 212 99% 0 0% 212 99% 177 82% 0 0% 172 97%
Hawaii 76 76 100% 73 96% 3 4% 76 100% 71 93% 0 0% 68 96%
Idaho 12 11 92% 11 92% 0 0% 11 92% 8 67% 0 0% 7 88%
Illinois 139 134 96% 115 83% 0 0% 115 83% 83 60% 0 0% 78 94%
Indiana 128 128 100% 126 98% 0 0% 126 98% 111 87% 0 0% 111 100%
Iowa 86 84 98% 79 92% 1 1% 80 93% 65 76% 0 0% 60 92%
Kansas 52 49 94% 50 96% 0 0% 50 96% 30 58% 0 0% 27 90%
Kentucky 77 77 100% 70 91% 1 1% 71 92% 51 66% 0 0% 33 65%
Louisiana 74 63 85% 67 91% 0 0% 67 91% 62 84% 0 0% 50 81%
Maine 21 20 95% 21 100% 0 0% 21 100% 16 76% 0 0% 12 75%
Maryland 136 130 96% 77 57% 0 0% 77 57% 75 55% 0 0% 73 97%
Massachusetts 204 202 99% 196 96% 3 1% 199 98% 186 91% 0 0% 181 97%
Michigan 83 82 99% 80 96% 1 1% 81 98% 77 93% 0 0% 75 97%
Minnesota 324 322 99% 303 94% 8 2% 311 96% 266 82% 0 0% 257 97%
Mississippi 52 47 90% 37 71% 1 2% 38 73% 26 50% 0 0% 26 100%
Missouri 61 60 98% 56 92% 0 0% 56 92% 44 72% 1 2% 42 95%
Montana 4 4 100% 4 100% 0 0% 4 100% 4 100% 0 0% 4 100%
Nebraska 38 37 97% 36 95% 0 0% 36 95% 33 87% 0 0% 33 100%
Nevada 49 46 94% 47 96% 0 0% 47 96% 30 61% 0 0% 29 97%
New Hampshire 19 19 100% 16 84% 1 5% 17 89% 16 84% 0 0% 14 88%
New Jersey 179 153 85% 158 88% 6 3% 164 92% 88 49% 0 0% 63 72%
New Mexico 11 11 100% 10 91% 0 0% 10 91% 8 73% 0 0% 8 100%
New York State 222 217 98% 215 97% 2 1% 217 98% 172 77% 0 0% 166 97%
North Carolina 174 157 90% 162 93% 5 3% 167 96% 133 76% 0 0% 125 94%
North Dakota 22 22 100% 22 100% 0 0% 22 100% 8 36% 0 0% 8 100%
Ohio 218 201 92% 196 90% 22 10% 218 100% 118 54% 2 2% 80 68%
Oklahoma 71 67 94% 56 79% 2 3% 58 82% 30 42% 0 0% 24 80%
Oregon 68 66 97% 65 96% 1 1% 66 97% 36 53% 0 0% 32 89%
Pennsylvania 166 154 93% 154 93% 1 1% 155 93% 140 84% 1 1% 125 89%
Rhode Island 21 21 100% 21 100% 0 0% 21 100% 21 100% 1 5% 20 95%
South Carolina 44 42 95% 41 93% 0 0% 41 93% 28 64% 0 0% 28 100%
South Dakota 12 12 100% 12 100% 0 0% 12 100% 5 42% 0 0% 4 80%
Tennessee 86 77 90% 81 94% 0 0% 81 94% 65 76% 0 0% 58 89%
Texas 560 560 100% 476 85% 9 2% 485 87% 355 63% 1 0% 338 95%
Utah 47 47 100% 45 96% 0 0% 45 96% 32 68% 0 0% 31 97%
Vermont 7 6 86% 6 86% 1 14% 7 100% 5 71% 0 0% 4 80%
Virginia 210 199 95% 193 92% 6 3% 199 95% 136 65% 0 0% 125 92%
Washington 207 205 99% 181 87% 3 1% 184 89% 112 54% 0 0% 106 95%
West Virginia 20 17 85% 20 100% 0 0% 20 100% 19 95% 0 0% 16 84%
Wisconsin 93 92 99% 82 88% 8 9% 90 97% 72 77% 0 0% 68 94%
Wyoming 2 2 100% 1 50% 0 0% 1 50% 1 50% 0 0% 1 100%
Cities**
Chicago 52 51 98% 47 90% 1 2% 48 92% 31 60% 0 0% 28 90%
District of Columbia 14 14 100% 14 100% 0 0% 14 100% 14 100% 0 0% 14 100%
Houston 87 84 97% 76 87% 1 1% 77 89% 50 57% 0 0% 45 90%
New York City 643 637 99% 617 96% 3 0% 620 96% 534 83% 0 0% 514 96%
Philadelphia 97 93 96% 91 94% 0 0% 91 94% 73 75% 0 0% 66 90%
San Antonio 35 34 97% 32 91% 2 6% 34 97% 30 86% 0 0% 29 97%
Territories
American Samoa 2 2 100% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%
Guam 16 16 100% 2 13% 2 13% 4 25% 0 0% 0 0% 0 0%
N. Mariana Islands 7 6 86% 7 100% 0 0% 7 100% 5 71% 0 0% 5 100%
Puerto Rico 297 1 0% 1 0% 0 0% 1 0% 0 0% 0 0% 0 0%
US Virgin Islands 3 2 67% 2 67% 0 0% 2 67% 2 67% 0 0% 2 100%
Freely Associated Island Nations
Republic of the Marshall Islands 26 12 46% 8 31% 0 0% 8 31% 0 0% 0 0% 0 0%
The Federated States of Micronesia 12 10 83% 12 100% 0 0% 12 100% 0 0% 0 0% 0 0%
Republic of Palau 7 7 100% 7 100% 0 0% 7 100% 7 100% 0 0% 7 100%
Table 4.1 Data
table-4.1
Download
Download

Source: National Perinatal Hepatitis B Prevention Program (PHBPP), Immunization Services Division, CDC.

PEP (post-exposure prophylaxis): The number of infants who received PEP at birth (hepatitis B immune globulin and first dose of hepatitis B vaccine) for hepatitis B virus infection.

HBIG: hepatitis B immune globulin.

HBsAg: hepatitis B surface antigen.

anti-HBs: antibody to hepatitis B surface antigen.

* Data only include infants followed by the CDC Perinatal Hepatitis B Prevention Program. National and jurisdictional level hepatitis B vaccination coverage rates are available via annual The Morbidity and Mortality Weekly Report (MMWR) publications of National Immunization Survey data and via VaxView.

† Post-vaccination serologic testing (PVST) includes a test for HBsAg, anti-HBs, or both. Results from PVST may be reported as HBsAg positive, HBsAg negative and immune or not immune, or indeterminate.

§ Anti-HBs ≥10 mIU/mL.

¶ Percentage is among infants that completed the vaccine series and received PVST.

** City data are mutually exclusive from state data.

Print
Content Source:
About Division of Viral Hepatitis